Birzeit Pharmaceutical Company Ltd

Birzeit Pharmaceutical Company Ltd has a strong liquidity position, as evidenced by a current ratio of 8.37, indicating that the company holds significantly more current assets than current liabilities. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage. However, the company reported negative operating and free cash flows of -$1,006,030 and -$1,331,630, respectively, which may signal short-term cash flow challenges.

Profitability metrics show a negative return on equity (ROE) of -1.44% and a negative return on assets (ROA) of -1.19%, indicating that the company is not generating returns for its shareholders or effectively utilizing its assets. These figures are below the typical performance of the pharmaceutical industry, which generally expects positive ROE and ROA due to the high-margin nature of the sector.

The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. This lack of diversification may expose the company to higher operational and market risks if demand for its pharmaceutical products declines or if regulatory changes impact its operations. There is no geographic breakdown provided, but the company is based in Palestine, which may limit its exposure to international markets and increase regional economic and political risks.

The company reported a net loss of -$1,441,470 in the latest period, and while no specific growth trajectory is provided, the negative net income and cash flows suggest a challenging operating environment. The absence of capital expenditures and the lack of a clear growth strategy may indicate a focus on cost control rather than expansion.

Risk factors include the company's negative net income and cash flows, which could affect its ability to fund operations and invest in future growth. The company has no immediate filing-based liquidity or dilution flags, and dilution risk is assessed as low. However, the negative operating cash flow and net loss may raise concerns about the company's long-term financial stability.

Recent events include the latest financial filing, which shows a net loss and negative cash flows. No recent earnings call transcripts or other material events are available in the provided data.

Operating income surged 40.2% year-over-year to $10.7 million, demonstrating strong top-line operational efficiency.

Free cash flow exploded 188.2% to $9.1 million, indicating robust cash generation capabilities.

The company maintains a zero debt-to-equity ratio, significantly outperforming the 0.18 industry median.

Revenue grew 18.0% year-over-year to nearly $48 million, showing consistent top-line expansion.

Four-year net income CAGR is negative at -0.3%, revealing long-term earnings stagnation.

Cash conversion ratio of 0.7 is below the 0.95 industry median, suggesting weaker cash quality.

Return on assets is negative at -1.2%, indicating inefficient use of company assets.